Alphamab Oncology (HKG:9966) said the Center for Drug Evaluation of China's National Medical Products Administration approved the new investigational drug application for its new anti-tumor drug after the phase I/II clinical trial, according to a Tuesday filing with the Hong Kong bourse.
JSKN033-102 is a high-concentration subcutaneous co-formulation consisting of anti-HER2 bispecific antibody-drug conjugate and PD-L1 immune checkpoint inhibitor, the filing added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.